Fig. 5: IV BCG boosts NK cell antitumor function. | Nature Communications

Fig. 5: IV BCG boosts NK cell antitumor function.

From: Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung

Fig. 5

a Schematic diagram showing treatment strategy for panels (a, b) and NK cell frequency in the lungs (n = 6 mice/group, from one experiment representative of three independent experiments). b Quantification of Granzyme B, IFN-γ, CD107a and CD11b expression in lung NK cells (n = 6 mice/group, from one experiment representative of three independent experiments). c Schematic diagram showing experimental setup and in vitro cytotoxicity of purified lung NK cells against target B16-F10 tumor cells, pooled from three independent experiments with n = 2 mice per condition. d Survival curve of WT or Perf−/− mice bearing B16-F10-B2m−/− lung metastases (n = 6 mice for WT and n = 5 for Perf−/− mice, from one experiment). e Survival curves of mice bearing B16-F10 lung metastases (n = 12 mice for PBS IV and BCG IV and n = 6 mice for BCG IV + NK depletion, pooled from two independent experiments). P values were calculated using two-tailed unpaired Student’s t test at a 95 % CI (a–c) or log-rank (Mantel-Cox) test (d, e). Data is depicted as mean ± SEM. PBS phosphate-buffered saline, IV intravenous, B2m Beta-2 microglobulin, Perf perforin, NK natural killer, GZMB granzyme B, IP intraperitoneal.

Back to article page